This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Tecemotide Following Concurrent Chemo-radiotherapy...
Clinical trial

Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer (START2)

Read time: 1 mins
Last updated:27th Jan 2014

This is a multi-center, double-blind, placebo-controlled, randomized, Phase 3 trial in subjects with unresectable stage III non-small cell lung cancer (NSCLC) who have demonstrated either stable disease or objective response following primary concurrent chemo-radiotherapy (CRT), comparing overall survival (OS) time in subjects treated with tecemotide versus subjects treated with tecemotide-matching placebo.

Category Value
Study start date 2014-01-27

View full details